Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.62 |
| ▸ | RAB9A | P51151 | 8/20 | 0.62 |
| ▸ | NPC1 | O15118 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2554297 | 0.89 | SMN1; SMN2 (0.78) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL18674667 | 0.88 | SMN1; SMN2 (0.63) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL2557611 | 0.88 | SMN1; SMN2 (0.80) | FFAR2SMN1; SMN2RAB9ANPC1MEN1 | |
| SCHEMBL21206043 | 0.84 | SMN1; SMN2 (0.81) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL7203008 | 0.82 | SMN1; SMN2 (0.67) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL2228768 | 0.81 | RAB9A (0.57) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL3230851 | 0.80 | FFAR2 (0.50) | FFAR2SMN1; SMN2RAB9ANPC1L3MBTL1 | |
| SCHEMBL29787710 | 0.80 | FFAR2 (1.00) | FFAR2SMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL19406629 | 0.80 | FFAR2 (1.00) | FFAR2SMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL2037008 | 0.80 | FFAR2 (1.00) | FFAR2SMN1; SMN2RAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114773249-B | Compounds, pharmaceutical compositions and methods for treating inflammatory diseases | 艾匹克治疗公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-114773249-A | Compounds, pharmaceutical compositions and methods for treating inflammatory diseases | 艾匹克治疗公司 | 2022-07-22 | — | — | CN | disclosed |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2021-07-27 | — | — | US | disclosed |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2020-11-05 | — | — | US | disclosed |
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2020-09-22 | — | — | US | disclosed |
| US-20200148636-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | EPICS THERAPEUTICS (BE) | 2020-05-14 | — | — | US | disclosed |
| US-10577318-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2020-03-03 | — | — | US | disclosed |
| EP-3610872-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EPICS THERAPEUTICS (BE) | 2020-02-19 | — | — | EP | disclosed |
| US-20190300478-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2019-10-03 | — | — | US | disclosed |
| EP-3074008-B1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATION | EPICS THERAPEUTICS (BE) | 2019-09-04 | — | — | EP | disclosed |
| US-9221840-B2 | Treating protein folding disorders with small molecule CFTR correctors | DISCOVERYBIOMED INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221840-B2 | Treating protein folding disorders with small molecule CFTR correctors | DISCOVERYBIOMED INC. (US) | 2015-12-29 | — | — | US | disclosed |
| WO-2015078949-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EUROSCREEN SA (BE) | 2015-06-04 | — | — | WO | disclosed |
| CN-102812003-B | Pyrrolidine Or Thiazolidine Carboxylic Acid Derivatives, Pharmaceutical Composition And Methods For Use In Treating Metabolic Disordersas As Agonists Of G- Protein Coupled Receptor 43 (GPR43) | EUROSCREEN SA | 2015-01-21 | — | — | CN | disclosed |
| US-20140073632-A1 | TREATING PROTEIN FOLDING DISORDERS WITH SMALL MOLECULE CFTR CORRECTORS | THE UAB RESEARCH FOUNDATION (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073632-A1 | TREATING PROTEIN FOLDING DISORDERS WITH SMALL MOLECULE CFTR CORRECTORS | THE UAB RESEARCH FOUNDATION (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130023539-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | EUROSCREEN S.A. (BE) | 2013-01-24 | — | — | US | disclosed |
| WO-2012158913-A2 | TREATING PROTEIN FOLDING DISORDERS WITH SMALL MOLECULE CFTR CORRECTORS | DISCOVERYBIOMED INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| EP-2513053-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERSAS AS AGONISTS OF G- PROTEIN COUPLED RECEPTOR 43 (GPR43) | Euroscreen S.A. (BE) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011073376-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERSAS AS AGONISTS OF G- PROTEIN COUPLED RECEPTOR 43 (GPR43) | EUROSCREEN S.A. (BE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | FFAR2 33/4885SMN1; SMN2 4049/4885RAB9A 928/4885 |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | FFAR2 33/4885SMN1; SMN2 4049/4885RAB9A 928/4885 |
| US-20200148636-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | GPR119, GPR65, GPR84 | FFAR2 22/4885SMN1; SMN2 4224/4885RAB9A 2179/4885 |
| US-20140073632-A1 | TREATING PROTEIN FOLDING DISORDERS WITH SMALL MOLECULE CFTR CORRECTORS | CFTR, CLCN2, SLC47A1 | FFAR2 2536/4885SMN1; SMN2 1902/4885RAB9A 337/4885 |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | FFAR2 33/4885SMN1; SMN2 4049/4885RAB9A 928/4885 |
| US-20130023539-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | GPR119, GPR65, GPR84 | FFAR2 22/4885SMN1; SMN2 4224/4885RAB9A 2179/4885 |
| US-10577318-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | FFAR2 26/4885SMN1; SMN2 4163/4885RAB9A 892/4885 |
| US-20190300478-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | FFAR2 32/4885SMN1; SMN2 4076/4885RAB9A 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.